ranitidine or famotidine

PreclinicalSmall molecule

SStanford University

ranitidine or famotidine is one of 3 small molecule programs targeting Laryngomalacia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LaryngomalaciaActive, not recruiting

LaryngomalaciaPreclinical

Active, not recruiting

Competition

Competitive Landscape

2 competitors in Laryngomalacia

#DrugCompanyPhaseTrials

Pepcid

KKenvue Brands

Phase 2

1 2

Prilosec

DDexcel Pharma Technologies Ltd.

Phase 1

1 3

ranitidine or famotidine

SStanford University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Laryngomalacia1 trial

In Infants With Laryngomalacia, Does Acid-Blocking Medication Improve Respiratory Symptoms?

Withdrawn·SStanford University·N/A·NCT02700087

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ranitidine or famotidine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ranitidine or famotidine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ranitidine or famotidine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Stanford University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SStanford University

ranitidine or famotidine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Laryngomalacia1 trial

References

Drug Info

Quick Facts

Related News